Skip to content
Text “Loti” to 833-962-6682 to join the Loti Labs VIP Group!
Loti Labs Resources Blog

LGD-4033 (Ligandrol) Research: Pharmacokinetics & 2026 Study Data

<p> […] </p>

LGD-4033 (Ligandrol) Research Laboratory

LGD-4033 is not FDA-approved and is strictly not for human consumption : it is available for Research Use Only (RUO) by qualified laboratory investigators.

Originally developed by Ligand Pharmaceuticals and currently under investigation by Viking Therapeutics, LGD-4033 is the subject of completed Phase I and Phase II clinical trials. As of 2026, it remains an Investigational New Drug (IND) available exclusively for Research Use Only (RUO) applications by qualified laboratory investigators. Its developmental code VK5211 identifies it within Viking’s clinical pipeline.

As of 2026, the research landscape surrounding LGD-4033 has expanded significantly. This guide provides a comprehensive technical overview of LGD-4033, including its chemical properties, molecular mechanism, pharmacokinetic profile, and the most recent regulatory developments affecting its status in laboratory environments.

What Is LGD-4033? Defining the VK5211 SARM

Research Use Only: LGD-4033 (Ligandrol) is an investigational compound available exclusively for laboratory and in vitro/in vivo research applications. It is not approved by the FDA for human consumption, therapeutic use, or dietary supplementation.

LGD-4033 is a high-affinity, orally bioavailable, non-steroidal Selective Androgen Receptor Modulator. Unlike traditional testosterone derivatives, which possess a four-ring steroid nucleus, LGD-4033 is a nonsteroidal ligand with a substituted pyrrolidinyl-benzonitrile structure rather than an aryl-propionamide (PubChem CID 44137686). That structural difference matters, because the molecule interacts with the androgen receptor (AR) without being a substrate for 5-alpha reductase or aromatase.

In clinical research, LGD-4033 is often referred to by its developmental name, VK5211.

Chemical Structure & Pyrrolidinyl-Benzonitrile Core

The chemical identity of LGD-4033 is defined by its IUPAC designation: 4-[(2R)-2-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]pyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile. The molecule is built around a pyrrolidinyl-benzonitrile core and carries trifluoromethyl groups, as the IUPAC name above shows. Claims that those groups let it bypass first-pass hepatic metabolism better than earlier compounds are not supported by a primary source we could verify, so they are not made here.

Technical specifications for LGD-4033 include:

  • Molecular Formula: C14H12F6N2O
  • Molecular Weight: 338.25 g/mol
  • CAS Number: 1165910-22-4
  • PubChem CID: 44137686

The pyrrolidin-1-yl moiety, combined with the trifluoro-hydroxyethyl side chain, creates a unique spatial orientation that fits precisely into the ligand-binding domain (LBD) of the androgen receptor. Reported binding affinity values for this and other receptor ligands come from different assay systems, and values obtained that way cannot be used on their own to rank potency between compounds.

Mechanism of Action: Tissue Selectivity and Androgen Receptor Binding

The mechanism of action for LGD-4033 is rooted in its role as a partial-to-full agonist of the Androgen Receptor (AR). Upon oral administration in research models, LGD-4033 crosses the cell membrane and binds to the AR in the cytoplasm. This binding triggers a conformational change in the receptor, leading to its translocation into the nucleus. Once inside the nucleus, the AR-LGD-4033 complex binds to specific DNA sequences known as androgen response elements (AREs), initiating the transcription of genes involved in protein synthesis and osteoblastic activity.

Tissue selectivity has been proposed to involve differences in receptor conformation and in which coactivator or corepressor proteins are recruited in a given tissue. Compound-specific structural and functional evidence for that mechanism in LGD-4033 is not available to us, so it should be read as a hypothesis and not as an established property.

Pharmacokinetics of LGD-4033 in Clinical Research

Quick Reference, LGD-4033 chemical identity: Molecular formula C14H12F6N2O | Molecular weight 338.25 g/mol | PubChem CID 44137686 | The published short-term human study reports a long elimination half-life and dose-proportional accumulation on repeated administration (Basaria 2013, PMID 22459616), without a confirmed numeric half-life in the record we read.
LGD-4033 Clinical Trial Data and Pharmacokinetics

Understanding the pharmacokinetics of LGD-4033 matters when designing in vivo studies. The published short-term human study describes a long elimination half-life and accumulation proportional to dose on repeated administration. Specific bioavailability and peak-concentration figures that circulate online could not be confirmed against that record, so they are not stated here.

Half-Life, Absorption, and Elimination Rates

The short-term placebo-controlled study by Basaria and colleagues (2013, J Gerontol A Biol Sci Med Sci 68:87-95, PMID 22459616) reported a long elimination half-life and dose-proportional accumulation when the compound was given daily for 21 days. The abstract does not give a numeric half-life. Figures such as 24 to 36 hours, and oral bioavailability above 70%, are repeated widely online but we could not verify them against the primary report, so this guide does not assert them.

The metabolism of LGD-4033 primarily involves hepatic pathways, though it is not a 17-alpha-alkylated compound, which distinguishes it from many oral anabolic steroids. Elimination is primarily through urinary and fecal routes. The published study reported accumulation proportional to dose on repeated administration.

Clinical Trial History and Emerging 2026 Research Trends

LGD-4033 is among the more documented selective androgen receptor modulators in the published literature, although the human record is short.

That record is the placebo-controlled study by Basaria and colleagues (2013, J Gerontol A Biol Sci Med Sci 68:87-95, PMID 22459616): 76 healthy men aged 21 to 50, randomised to placebo or ascending daily doses for 21 days, with blood counts, chemistries, lipids, prostate-specific antigen, electrocardiogram, hormones and body composition measured during the study and for five weeks afterwards. Longer human data are not available, and nothing in that study supports conclusions about long-term safety.

LGD-4033 vs. RAD-140 (Testolone): Comparative Analysis

Researchers often compare LGD-4033 to RAD-140 (Testolone), as both are potent SARMs but exhibit distinct pharmacological profiles. Understanding these differences is vital for selecting the appropriate ligand for specific investigational aims.

Why this guide gives no potency ranking

Published Ki values for these two compounds come from separate studies that used different assay systems, different endpoints and different conditions. Values obtained that way cannot establish which compound binds or acts more potently, so no ranking and no comparison table is given here. A comparison would need matched assays and matched endpoints run side by side.

The same limit applies to half-life and to selectivity ratios. The short-term human study of LGD-4033 describes a long elimination half-life without a confirmed numeric value in the record we read, and we have no matched pharmacokinetic record for RAD-140, so no comparative figures are stated.

LGD-4033 vs. Ostarine (Enobosarm): Key Distinctions

Ostarine (Enobosarm, MK-2866) represents the most extensively clinically trialed SARM alongside LGD-4033. Comparing how far each compound suppresses hormones would need matched studies. The published records differ in design, so no ranking is given here. Both compounds are on WADA’s S1.2 Prohibited List and are strictly RUO.

Safety Advisory: In a short-term placebo-controlled human study (Basaria 2013, PMID 22459616), total testosterone, sex hormone-binding globulin, HDL cholesterol and triglycerides were suppressed in a dose-dependent way over 21 days. Liver injury has been described in case reports involving products from unverified sources. The available human data are short-term and limited, and they do not establish long-term safety or the absence of endocrine or hepatic risk. All research use requires institutional review and qualified oversight.

Safety Profile and Documented Preclinical Observations

LGD-4033 has progressed further in clinical study than most selective androgen receptor modulators, but the available human data remain short-term and limited, and the compound has measurable physiological effects that must be monitored in a research setting. It is important to note the following: LGD-4033 is an investigational compound supplied strictly for laboratory and in vitro/in vivo research applications. It is not approved for human consumption, therapeutic use, or dietary supplementation.

Testosterone Suppression and Lipid Metabolism

In the Basaria 2013 study, total testosterone and sex hormone-binding globulin were suppressed in a dose-dependent way. Free testosterone and follicle-stimulating hormone were significantly suppressed only at the highest dose investigated. Luteinizing hormone was not reported as significantly changed in that study, so a blanket statement that the compound suppresses both gonadotropins across the investigated range is not supported.

Lipids changed as well. The same study reported dose-dependent reductions in high-density lipoprotein cholesterol and in triglycerides. Hormone levels and lipids returned to baseline after the compound was discontinued in that 21 day study. What happens over longer periods has not been established, so cardiovascular markers belong in any extended research protocol.

Hepatotoxicity and Drug-Induced Liver Injury (DILI) in Research Models

Hepatic signals are usually discussed as elevations in liver enzymes (ALT and AST). In the Basaria 2013 study, AST, ALT, hemoglobin, prostate-specific antigen and QT interval did not change significantly over 21 days. That is a short-term result in a small group and it does not rule out hepatic risk. Researchers should use high-purity material and verify identity and purity, because contaminants and degradation products are a hazard in their own right. General storage and stability practice applies here as well, although this compound is handled as a liquid or powder rather than as a lyophilised peptide.

Published case reports describe cholestatic liver injury in people who took LGD-4033 products obtained from unverified sources, with markedly elevated aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Institutional research protocols should include baseline and periodic hepatic panels (AST, ALT, bilirubin) as a standard safety measure.

Hormone effects in the published short-term human study were limited to dose-dependent suppression of total testosterone and sex hormone-binding globulin, with free testosterone and follicle-stimulating hormone suppressed at the highest dose investigated only. Luteinizing hormone was not reported as significantly changed.

LGD-4033 FDA and WADA Regulatory Status 2026

LGD-4033 Regulatory Status 2026: FDA and WADA

Regulatory Status 2026: LGD-4033 remains on WADA’s Prohibited List (S1.2 : Other Anabolic Agents) and is not an FDA-approved drug. FDA Warning Letters issued in 2025-2026 target vendors marketing SARMs as dietary supplements. Research procurement must comply with applicable federal and institutional guidelines.

The regulatory environment for SARMs has tightened significantly in 2026, driven by an increase in mislabeled products in the consumer market. Researchers must be aware of the legal distinctions between “Research Use Only” compounds and prohibited dietary supplements.

Investigational New Drug Status

LGD-4033 remains an Investigational New Drug (IND). It has not been approved by the FDA for the treatment of any medical condition. In late 2025 and early 2026, the FDA issued several FDA Warning Letters to vendors (notably the Titan SARMs LLC enforcement action) who were mislabeling SARMs as dietary supplements or making specific health claims. These enforcement actions underscore the necessity for vendors like Loti Labs to maintain strict RUO compliance, focusing on analytical transparency through ICP-MS testing and COA availability.

A significant 2026 development: Viking Therapeutics’ Q1 2026 earnings report (May 11, 2026) confirmed that VK5211 (LGD-4033) is now “positioned for partnering” rather than active internal Phase III development, with Viking redirecting primary resources to VK2735, their GLP-1/GIP co-agonist for obesity. This does not alter LGD-4033’s IND status but signals a shift in the pharmaceutical development timeline.

WADA Prohibited List and Anti-Doping Enforcement

LGD-4033 is explicitly listed on the WADA Prohibited List under Category S1.2 (Other Anabolic Agents). It is banned at all times (both in-competition and out-of-competition) for all athletes subject to the World Anti-Doping Code. Due to its long half-life and the presence of long-term metabolites, LGD-4033 has a significant detection window in urine and blood samples. Anti-doping laboratories have developed highly sensitive liquid chromatography-mass spectrometry (LC-MS) assays capable of detecting LGD-4033 metabolites weeks after the final administration in a research subject.

WADA-accredited laboratories detect LGD-4033 via LC-MS/MS analysis targeting both the parent compound and its dihydroxylated metabolites in urine : the latter extending the detection window to approximately 21 days post-administration. As of 2025-2026, over 60 Adverse Analytical Findings (AAFs) involving LGD-4033 have been recorded across powerlifting and track-and-field disciplines, making it one of the most commonly detected prohibited SARMs. USADA has issued explicit warnings regarding supplement contamination with LGD-4033, as trace amounts in unlabeled products may trigger positive anti-doping tests.

Frequently Asked Questions About LGD-4033

Is LGD-4033 FDA approved?

No. As of 2026, LGD-4033 (Ligandrol) remains classified as an Investigational New Drug (IND) and is not approved by the FDA for human consumption, therapeutic use, or dietary supplementation. It is available exclusively as a research-use-only (RUO) compound for qualified laboratory investigators under applicable federal and institutional guidelines.

What does the published record say about the half-life of LGD-4033?

The short-term human study (Basaria 2013, PMID 22459616) reports a long elimination half-life and dose-proportional accumulation on repeated administration. It does not give a numeric half-life in its abstract. Figures such as 24 to 36 hours circulate widely online, but we could not confirm them against that primary report, so they are not stated here.

Does LGD-4033 cause testosterone suppression?

In the short-term placebo-controlled study by Basaria and colleagues (2013, PMID 22459616), total testosterone and sex hormone-binding globulin were suppressed in a dose-dependent way over 21 days, and free testosterone and follicle-stimulating hormone were suppressed at the highest dose investigated only. Luteinizing hormone was not reported as significantly changed. Hormones and lipids returned to baseline after the compound was discontinued.

How does LGD-4033 compare to RAD-140 (Testolone)?

Both are nonsteroidal selective androgen receptor modulators supplied for research use only. Published binding and pharmacokinetic values for the two come from different studies and different assays, so they cannot be used to rank potency or to compare half-lives. A valid comparison would need matched assays and endpoints.

Can LGD-4033 cause liver damage?

Published case reports describe cholestatic liver injury in people who took LGD-4033 products from unverified sources, with elevated AST and ALT. In the controlled short-term study (Basaria 2013, PMID 22459616), AST and ALT did not change significantly over 21 days. That study was short and small, so it cannot rule out hepatic risk, and product impurities remain a separate hazard.

Is LGD-4033 legal for research purposes?

LGD-4033 is legal to acquire and use strictly for laboratory and in vitro/in vivo research applications in jurisdictions where no explicit prohibition exists. It is not approved as a dietary supplement and FDA Warning Letters issued in 2025-2026 targeted vendors marketing SARMs as such. WADA prohibits LGD-4033 in competitive athletes under the S1.2 classification.

What is the WADA detection window for LGD-4033?

LGD-4033 and its long-chain metabolites are detectable by WADA-compliant liquid chromatography-mass spectrometry (LC-MS/MS) assays for up to 21 days post-administration in research subjects. LGD-4033 is classified under WADA’s Prohibited List (S1.2 : Other Anabolic Agents) and is banned in all sports, both in-competition and out-of-competition.

Why did Viking Therapeutics pause development of VK5211 (LGD-4033)?

According to Viking Therapeutics’ Q1 2026 earnings report (May 11, 2026), VK5211 has been positioned for external partnering rather than continued internal Phase III development. Viking redirected its primary capital and clinical resources toward VK2735, its GLP-1/GIP co-agonist for obesity treatment, which demonstrated greater commercial potential. VK5211’s IND status and completed clinical data remain available for potential licensing partners.

What is the difference between Ligandrol, Anabolicum, and VK5211?

Ligandrol, Anabolicum, and VK5211 are all synonymous names for the identical chemical compound LGD-4033 (4-[(2R)-2-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]pyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile). “Ligandrol” is the common research name derived from Ligand Pharmaceuticals, “VK5211” is Viking Therapeutics’ clinical designation, and “Anabolicum” is a legacy trade name. All refer to the same molecular entity with PubChem CID 44137686.

Can LGD-4033 be detected in anti-doping drug tests?

Yes. WADA-accredited laboratories detect LGD-4033 via LC-MS/MS testing targeting both the parent compound and its dihydroxylated metabolites in urine. These long-chain metabolites extend the detection window to approximately 21 days post-administration. LGD-4033 is classified under WADA Prohibited List S1.2 (Other Anabolic Agents) and banned in-competition and out-of-competition in all sports.

What is the difference between LGD-4033 (Ligandrol) and Ostarine (Enobosarm)?

Both are WADA-prohibited SARMs available strictly for Research Use Only.

Research-use notice

This educational material discusses laboratory research concepts only. Loti Labs products are intended strictly for research and development use and are not for human consumption.

Ready to explore?

Browse high-purity research materials by format or view the full catalog.